CSL(ASX: CSL) at an 8-Year Low: Is Australia's Most Iconic Healthcare Stock Now a Bargain?

For years, Australian investors lived by one simple rule: never sell CSL.

It was not just a stock. It was a conviction. CSL (ASX: CSL) spent decades turning patient, long-term investors into some of the ASX's biggest winners. It did not make headlines by chasing trends or making bold promises. It just kept growing, year after year, through market crashes, recessions, and a global pandemic.

That reputation is now being tested in a way it never has been before.

In February 2026, CSL reported an 81% collapse in net profit, announced the sudden departure of its CEO, and saw its share price tumble to levels not seen since 2018. Investors who held through the good years are now sitting on heavy losses. New investors are asking whether this is the opportunity of a decade, or a warning sign to stay away.

Today, CSL trades near A$147, roughly 47% below its 52-week high of A$275.79 (as at March 2026).

The honest answer is that this is not a straightforward call. There are real reasons brokers still see significant upside. There are also real reasons the market remains cautious. Here is a plain-English breakdown of both sides so you can decide what makes sense for your situation.

What Went Wrong

The H1 FY2026 results, released 11 February 2026, shook the market on several fronts.

The 81% drop in statutory net profit sounds catastrophic. But much of that damage came from one-off restructuring charges and impairments totalling approximately US$1.1 billion. Strip those out, and the underlying profit (NPATA) came in at US$1.9 billion, down 7% on the prior period.

The real problems were more specific.

CSL Behring, the core plasma business, saw revenue fall 7%. Immunoglobulin sales declined 6%, partly due to US Medicare policy reforms, while albumin sales collapsed 27% because of hospital budget restrictions in China. These are not temporary inventory issues. China's policy reforms are structural, and they are still playing out.

The vaccine business had a rough half. US flu vaccination rates fell an estimated 12% last season, which hurt CSL Seqirus revenue and margins. The situation became serious enough that CSL paused its earlier plan to spin off Seqirus as a separately listed ASX company. That demerger, originally announced in August 2025, was put on hold in October 2025 when market conditions deteriorated. There is no firm timeline for when it might resume.

The CEO departed without warning. Paul McKenzie's retirement was announced the day before the results, adding a leadership question mark to an already complicated story. His replacement is Gordon Naylor, a 33-year CSL veteran who previously served as the company's CFO and President of Seqirus. The board was explicit about his appointment: Naylor is a steady hand who helped build CSL's global plasma and vaccine businesses from the ground up. He is not starting from scratch. He knows the company better than almost anyone.

All of this hit at once. That is why the market reacted so harshly.

‍

Why Brokers Are Still Backing CSL

Despite the tough headlines, most analysts have not walked away from CSL.

CSL Vifor, the nephrology division, grew 12% to US$1.24 billion in H1 FY2026. The company is also making real progress on its cost-cutting program, with approximately 60% of the targeted FY2026 savings already achieved by the time of the results. The full savings target remains US$500 to US$550 million annually by FY2028.

CSL has also launched an A$750 million on-market share buyback. Buying back stock near 8-year lows is a clear signal that the board believes the current price does not reflect the true value of the business.

For income-focused investors, CSL confirmed an interim dividend of US$1.30 per share, with an ex-dividend date of 10 March 2026 and a record date of 11 March 2026.

According to analyst consensus, 16 brokers covering CSL average a 12-month price target near A$210, with the high end reaching A$288. Jefferies holds a Buy rating with an A$237 target, viewing the China and vaccine headwinds as temporary.

‍

The Risks Worth Knowing

The widespread between analyst price targets tells you this is a genuine uncertainty story.

Macquarie downgraded CSL to Neutral in December 2025 with a A$188 target, citing three concerns. First, China's albumin restrictions are tied to permanent policy reforms, not a passing cycle. Second, a leadership transition always adds uncertainty, even with an experienced interim at the helm. Third, new drug classes are beginning to compete with some of CSL's core immunoglobulin therapies over the longer term.

Full-year FY2026 guidance was maintained at revenue growth of 2 to 3% and underlying profit growth of 4 to 7%. But management has flagged that performance is weighted toward the second half. Given that the first half disappointed, a lot is riding on that delivery.

‍

Investor Takeaway

Key points to keep in mind:

• The 81% statutory profit drop was driven by one-off costs, but underlying profit also fell 7%, so this is not just a one-off story
• China's albumin pressure and vaccine market headwinds are real and ongoing
• The Seqirus demerger has been paused, adding further strategic uncertainty
• The A$750 million buyback, cost-cutting progress, and US$1.30 interim dividend support the medium-term case
• Analyst consensus still sees meaningful upside, but the range of views is unusually wide
• H2 FY2026 results (due August 2026) are the real test of the recovery story

CSL remains one of Australia's highest-quality healthcare franchises. The question for investors right now is not whether CSL is a good business. It is whether the recovery will show up in the numbers soon enough to justify acting before the market catches on.

For investors who want to go deeper on ASX growth stocks and blue-chip recovery setups, ASR's Investing Report covers exactly this kind of situation with detailed analysis and risk-adjusted positioning guidance.

‍

Want a starting point? Download ASR's free Top-3 Stocks and Market Outlook Report for our analysts' latest views on where the opportunities are right now.

‍

‍

‍

This article is for informational and educational purposes only and does not constitute financial advice. Always consider your personal circumstances and consult a licensed financial adviser before making investment decisions.

‍